Compare Essex Property Trust, Inc. (ESS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Neurocrine Biosciences Inc — how do they compare? Essex Property Trust, Inc. trades at $298.07 (market cap $18.82B), while Neurocrine Biosciences Inc trades at $171.81 (market cap $17.30B). The key difference: Essex Property Trust, Inc. and Neurocrine Biosciences Inc are close in size by market cap, and Essex Property Trust, Inc. pays a 3.54% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| ESS | NBIX | |
|---|---|---|
Market Cap | $18.82B | $17.30B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $180.55 |
52-Week Low | $239.61 | $123.10 |
Enterprise Value | $25.54B | $16.39B |
Dividend Yield | 3.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Essex Property Trust (ESS) trades at $293.32, down 1.61% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 30.03% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include the upcoming Q2 2026 earnings release and inclusion in the Russell Microcap Index, reflecting positive momentum.
The outlook for ESS is cautiously optimistic, driven by robust West Coast rental demand and AI-driven employment growth. Risks include elevated debt levels and Seattle market weakness. Analysts maintain a mixed consensus with a $294.25 price target, suggesting limited near-term upside from current levels amid balanced sentiment.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
